France challenges patent for genetic screening of breast cancerBMJ 2001; 323 doi: http://dx.doi.org/10.1136/bmj.323.7313.589 (Published 15 September 2001) Cite this as: BMJ 2001;323:589
- Alexandre Dorozynski
The Institut Curie, France's top centre for research, diagnosis, and treatment of cancer, is challenging the patent awarded by the European patent office to the US company Myriad Genetics, of Salt Lake City, Utah, for a test to screen for predisposition to breast cancer.
The patent, granted last January, covers the BRCA1 gene. The French ministry of health and the ministry of research support the institute's initiative, claiming that the patent gives Myriad an abusive monopoly and threatens basic research. …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial